Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis... IntroductionLIBERATE (NCT01690299), a global phase 3b study in biologic‐naive patients with moderate to severe plaque psoriasis, demonstrated that significantly more patients receiving apremilast for 16 weeks achieved PASI‐75 (≥75% reduction from baseline in Psoriasis Area and Severity Index [PASI]) vs. placebo. A post hoc analysis found no significant difference in response rates among patients given apremilast vs. etanercept, an anti‐tumour necrosis factor‐α biologic agent.This report describes efficacy and safety outcomes from the LIBERATE apremilast‐extension phase (Weeks 16–104) in patients who continued apremilast treatment through 104 weeks, including those who switched from etanercept or placebo.Materials and methodsPatients and study designPatient selection, study design and study methods have been described in detail. Briefly, patients in the LIBERATE trial were adults in the United States, Canada, Europe (Belgium, Czech Republic, Estonia, Germany, Great Britain, Hungary, Latvia, the Netherlands) or Australia with chronic, moderate to severe plaque psoriasis with inadequate response, inability to tolerate or contraindication to treatment with ≥1 conventional systemic agent, and who were biologic‐naive. Eligible patients were randomized (1 : 1 : 1) to double‐blind treatment with apremilast 30 mg twice daily, etanercept subcutaneous injection 50 mg once weekly, or placebo for 16 weeks. At Week 16, placebo and etanercept http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the European Academy of Dermatology & Venereology Wiley

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study

Loading next page...
 
/lp/wiley/safety-and-efficacy-of-apremilast-through-104-weeks-in-patients-with-bFFgyxrnIi
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 European Academy of Dermatology and Venereology
ISSN
0926-9959
eISSN
1468-3083
D.O.I.
10.1111/jdv.14738
Publisher site
See Article on Publisher Site

Abstract

IntroductionLIBERATE (NCT01690299), a global phase 3b study in biologic‐naive patients with moderate to severe plaque psoriasis, demonstrated that significantly more patients receiving apremilast for 16 weeks achieved PASI‐75 (≥75% reduction from baseline in Psoriasis Area and Severity Index [PASI]) vs. placebo. A post hoc analysis found no significant difference in response rates among patients given apremilast vs. etanercept, an anti‐tumour necrosis factor‐α biologic agent.This report describes efficacy and safety outcomes from the LIBERATE apremilast‐extension phase (Weeks 16–104) in patients who continued apremilast treatment through 104 weeks, including those who switched from etanercept or placebo.Materials and methodsPatients and study designPatient selection, study design and study methods have been described in detail. Briefly, patients in the LIBERATE trial were adults in the United States, Canada, Europe (Belgium, Czech Republic, Estonia, Germany, Great Britain, Hungary, Latvia, the Netherlands) or Australia with chronic, moderate to severe plaque psoriasis with inadequate response, inability to tolerate or contraindication to treatment with ≥1 conventional systemic agent, and who were biologic‐naive. Eligible patients were randomized (1 : 1 : 1) to double‐blind treatment with apremilast 30 mg twice daily, etanercept subcutaneous injection 50 mg once weekly, or placebo for 16 weeks. At Week 16, placebo and etanercept

Journal

Journal of the European Academy of Dermatology & VenereologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off